Rectal Cancer
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (61186372COR3001)
- Details
ClinicalTrials.gov ID:
NCT06662786
Diagnosis Type:
NA
USOR Number:
- Address
,
P: